Prot #R910-3-AMD-1517: A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age Related Macular Degeneration

Project: Research project

Project Details

StatusFinished
Effective start/end date6/15/16 → 6/15/19

Funding

  • Parexel (Prot #R910-3-AMD-1517 // Prot #R910-3-AMD-1517)
  • Regeneron Pharmaceuticals, Inc. (Prot #R910-3-AMD-1517 // Prot #R910-3-AMD-1517)